- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05732142
Postpartum Integration of Vaccines and Contraception Trial (PIVoT)
Study Overview
Status
Conditions
Detailed Description
Using effective postpartum contraception allows postpartum people to prevent short inter-pregnancy intervals which are associated with an increased risk of maternal and infant morbidity and mortality. India is the country with the highest number of women with an unmet need for contraception, and postpartum and rural women are those with the greatest need. Uptake of postpartum contraception among women in rural India is low; less than half of postpartum women use contraception within the first year after delivery, and many births do not follow the recommended interval.
A promising intervention to address barriers to family planning care is to build on an existing successful health program, the infant vaccination program, by linking family planning services with infant vaccination. India's Ministry of Health has promoted community-based delivery of infant vaccinations, and monthly childhood vaccination services are offered at Village Health and Nutrition Days typically held at Anganwadi Community Centers. Six-week vaccination rates are high, indicating that these services are routinely used by families of young infants, which provides an opportunity to reach postpartum women simultaneously. This programming addresses gender-inequitable social norms and has shown to facilitate more successful family planning intervention but has not been studied among postpartum women. This study will adapt a gender-transformative family planning intervention to support community-based delivery of family planning with infant vaccination; this intervention has the potential to increase family planning use among postpartum women with unmet need in low-resources and rural settings.
This is a two-arm, cluster randomized-trial where postpartum women will be assigned to participation in the linked care model (PIVoT) or the standard of care (referring women to public health centers for family planning counseling and contraceptive provision). The study team will enroll 286 women in the study, 143 in each the intervention and control arms. Randomization will occur at the subcenter level. Participants will be recruited among postpartum women presenting for infant vaccination services at VHND.
Follow-up will occur with women at 6 months and 12 months postpartum and outcomes will be assessed via tablet-based surveys. In addition, a total of 40 in-depth interviews will take place with a group of PIVoT intervention participants, their husbands, and health care providers who delivered the program after completion of the study for further evaluation.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Maharashtra
-
Pune, Maharashtra, India
- Junnar Taluka
-
-
-
-
California
-
La Jolla, California, United States, 92093
- University of California, San Diego
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Postpartum women who delivered a baby within the past 12 weeks
- Speak Marathi
- Reside in rural Maharashtra
- Did not undergo sterilization, hysterectomy or immediate postpartum intrauterine device (IUD) placement
Exclusion Criteria:
- Currently pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: PIVoT
Gender-transformative family planning counseling and contraception provision at the time of infant vaccination
|
The PIVoT intervention is a 30-minute focused information exchange that supports shared contraceptive decision making.
The program includes a gender-equity and family planning curriculum covering basic family planning information as well as gender norms and son preference and interactive family planning method index cards (detailing method characteristics, use, duration of action, efficacy, side effects, and contraindications for each method).
The program is designed to support person-centered contraceptive choice and encourages women to consider joint family planning decision-making with male partners.
If a contraceptive method is desired, it will be provided by nurses who are trained to provide comprehensive family planning care.
|
|
No Intervention: Standard of care
Standard infant vaccination and family planning referrals
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of women using modern contraception at 6 months postpartum
Time Frame: 6 months after delivery
|
Contraceptive use will be measured through a self-reported survey collected at 6 months postpartum.
|
6 months after delivery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of women using modern contraception at 12 months postpartum
Time Frame: 12 months after delivery
|
Contraceptive use will be measured through a self-reported survey collected at 12 months postpartum
|
12 months after delivery
|
|
Feasibility, acceptability and appropriateness of the PiVOT intervention (qualitative) among participants
Time Frame: 6 months postpartum
|
In-depth interviews with a portion of PiVOT intervention participants
|
6 months postpartum
|
|
Feasibility, acceptability and appropriateness of the PiVOT intervention (qualitative) among providers of the program
Time Frame: 6 months postpartum
|
In-depth interviews with health care providers who delivered the PIVoT intervention after completion of the research study to further understand this outcome using qualitative data.
|
6 months postpartum
|
|
Feasibility, acceptability and appropriateness of the PiVOT intervention (qualitative) among husbands of participants
Time Frame: 6 months postpartum
|
In-depth interviews with husbands of participants (if recommended by their wife) after completion of the research study to further understand this outcome using qualitative data.
|
6 months postpartum
|
|
Feasibility, acceptability and appropriateness of the PiVOT intervention (quantitative)
Time Frame: 6 months after delivery
|
Self-reported survey questions using validated items regarding feasibility, acceptability and appropriateness of linked care will be collected at 6 months postpartum.
Participants will rate the 3 constructs using 12 items comprising 3 4-item scales with a 5-point Likert scale: completely agree=1, agree=2, neither agree nor disagree=3, disagree=4, completely disagree=5.
Higher scores on these items reflect more supportive attitudes toward the linked care model.
|
6 months after delivery
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Shahina Begum, PhD, Indian Council of Medical Research-National Institute for Research in Reproductive and Child Health
- Principal Investigator: Sarah Averbach, MD, MAS, University of California, San Diego
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 804819
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Contraception
-
Virginia Commonwealth UniversityCompletedPregnancy Related | Contraception | Contraception Behavior | Contraception Use
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Medical University of South CarolinaSociety of Family PlanningCompletedContraception | Contraception BehaviorUnited States
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedFemale Contraception | ContraceptionUnited States, Israel
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Janssen Pharmaceutica N.V., BelgiumCompleted
-
Montefiore Medical CenterSociety of Family PlanningCompletedContraception | Breastfeeding | Postpartum ContraceptionUnited States